

December 28, 2024

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Intimation of further investment in Panacea Biotec Inc. made by the Company's material subsidiary, Panacea Biotec Pharma Limited

Ref.: Our letter dated June 22, 2024 under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is in continuation to our intimation letter dated June 22, 2024, wherein we have informed about the incorporation of wholly owned subsidiary company, Panacea Biotec Inc. ("PB Inc.") by the Company's material subsidiary, Panacea Biotec Pharma Limited ("PBPL") and an investment of US\$ 75,000 (~Rs.6.23 million) made by PBPL in the shares of common stock of PB Inc.

In this regard, we would like to further inform you that on December 27, 2024, PBPL made further investment of US\$ 9,25,000 (~Rs.7.92 Crore) in PB Inc. as subscription for 9,25,00,000 shares of common stock of PB Inc. at a price of US\$ 0.01 per share.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, are given in **Annexure A** to this letter.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For Panacea Biotec Ltd.

Vinod Goel
Group CFO and Head Legal
& Company Secretary

Annexure – A

S. No.	Particulars	Details
i)	Name of the target entity, details in brief such as size, turnover etc.;	Panacea Biotec Inc. (“WOS”) was incorporated as a wholly owned subsidiary company of the Company’s material subsidiary viz. Panacea Biotec Pharma Ltd. (“ PBPL ”). Authorised Share Capital – 1 billion shares of US\$ 0.01 each aggregating to US\$ 10 million. Turnover: N.A. (Yet to commence business).
ii)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at arm’s length	Panacea Biotec Inc. being a step-down subsidiary of the Company is a Related Party of the Company and other group companies. The investment made by PBPL in PB Inc. is in the nature of related party transactions and is on an arm’s length basis. Save and except as above, none of the promoter / promoter group / group companies of the Company have any interest in WOS.
iii)	Industry to which the entity being acquired belongs	Healthcare
iv)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The WOS has been set-up with an objective of establishing presence in the world’s largest healthcare market in US by pursuing comprehensive range of activities, including the buying, selling, marketing, importing, exporting, distributing, and dealing in services and products related to health and wellness, such as nutrition, dietary supplements, OTC drugs, medical devices, prescription drugs, and vaccines. The investment made by PBPL in WOS is to facilitate the capex and working capital requirements of PB Inc. and is in furtherance of its business. The business of the WOS is in line with the business activities of the Company and PBPL
v)	Brief details of any governmental or regulatory approvals required for the acquisition	No such approval is required
vi)	Indicative time period for completion of the acquisition	Not Applicable
vii)	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash

S. No.	Particulars	Details
viii)	Cost of acquisition and/or the price at which the shares are acquired	PBPL has invested an amount of US\$ 9,25,000 (~Rs.7.92 Crore) for acquisition of 9,25,00,000 shares of common stock of Panacea Biotec Inc. at a price of US\$ 0.01 per share.
ix)	Percentage of shareholding / control acquired and / or number of shares acquired	PBPL will hold 100,000,000 shares of common stock of WOS representing 100% of the issued shareholding therein.
x)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	The main objects of the WOS shall encompass a comprehensive range of activities, including the buying, selling, marketing, importing, exporting, distributing, and dealing in services and products related to health and wellness, such as nutrition, dietary supplements, OTC drugs, medical devices, prescription drugs, and vaccines. Date of incorporation: April 09, 2024 Turnover for the last 3 years: Not Applicable. Country: United States of America